RARRES2

Across TCGA pan-cancer cohorts, RARRES2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RARRES2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RARRES2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RARRES2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

GBM, COAD, and LSCC are the cancer types where RARRES2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.266	0.501	.006	19	view →
COAD	DFS	Median	II,III,IV	0.875	1.000	.015	12	view →
LSCC	DFS	Median	II,III,IV	0.828	1.000	.002	12	view →
PDAC	DFS	Quartile	III,IV	0.227	0.898	.002	11	view →
CCRCC	DFS	Tertile	II,III,IV	0.260	0.784	.026	7	view →
HNSC	OS	Tertile	All	0.899	0.797	.042	1	view →
LUAD	OS	Median	All	0.924	0.718	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RARRES2–GBM (OS)

Open the GBM breakdown →